1. Mazzaferri EL 2000 Thyroid diseases: tumors. Radioiodine and other treatment and outcomes. In: Braverman LE, Utiger, R.D. (ed) Werner & Ingbar's The Thyroid, Eight Edition, 2000 ed. Lipincott Williams & Wilkins, pp 904-930.
2. Seidlin SM, Marinelli, L.D., Oshry, E. 1946 Radioactive iodine thearpy Journal of the American Medical Association Dec 7, 1946.
3. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-28.
4. Dai G, Levy O, Carrasco N 1996 Cloning and characterization of the thyroid iodide transporter. Nature 379:458-60.
5. Smanik PA, Liu Q, Furminger TL, et al. 1996 Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun 226:339-45.
6. Selmi-Ruby S, Watrin C, Trouttet-Masson S, et al. 2003 The porcine sodium/iodide symporter gene exhibits an uncommon expression pattern related to the use of alternative splice sites not present in the human or murine species. Endocrinology 144:1074-85.
7. Pinke LA, Dean DS, Bergert ER, Spitzweg C, Dutton CM, Morris JC 2001 Cloning of the mouse sodium iodide symporter. Thyroid 11:935-9.
8. Tazebay UH, Wapnir IL, Levy O, et al. 2000 The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 6:871-8.
9. Dohan O, De la Vieja A, Paroder V, et al. 2003 The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24:48-77.
10. Lew O, Dai G, Riedel C, et al. 1997 Characterization of the thyroid Na+/I- symporter with an anti-COOH terminus antibody. Proc Natl Acad Sci U S A 94:5568-73.
11. Paire A, Bernier-Valentin F, Selmi-Ruby S, Rousset B 1997 Characterization of the rat thyroid iodide transporter using anti-peptide antibodies. Relationship between its expression and activity. J Biol Chem
12. De La Vieja A, Dohan O, Levy O, Carrasco N 2000 Molecular analysis ofthe sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 80:1083-105.
13. Riedel C, Dohan O, De la Vieja A, Ginter CS, Carrasco N 2001 Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer. Trends Biochem Sci 26:490-6.
14. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC 2001 Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 86:3327-35.
15. Carrasco N 1993 Iodide transport in the thyroid gland. Biochim Biophys Acta 1154:65-82.
16. Wolff J 1998 Perchlorate and the thyroid gland. Pharmacol Rev 50:89-105.
17. Yoshida A, Sasaki N, Mori A, et al. 1997 Different electrophysiological character of I-, ClO4-, and SCN- in the transport by Na+/I- symporter. Biochem Biophys Res Commun 231:731-4.
18. Yoshida A, Sasaki N, Mori A, et al. 1998 Differences in the electrophysiological response to I-and the inhibitory anions SCN- and ClO-4, studied in FRTL-5 cells. Biochim Biophys Acta 1414: 231-7.
19. Eskandari S, Loo DD, Dai G, Levy O, Wright EM, Carrasco N 1997 Thyroid Na+/I- symporter. Mechanism, stoichiometry, and specificity. J Biol Chem 272:27230-8.
20. Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N 2001 Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 86:2697-700.
21. Levy O, De la Vieja A, Ginter CS, Riedel C, Dai G, Carrasco N 1998 N-linked glycosylation of the thyroid Na+/I- symporter (NIS). Implications for its secondary structure model. J Biol Chem 273:22657-63.
22. Riedel C, Levy O, Carrasco N 2001 Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 276:21458-63.
23. Dohan O, Ginter, Ch., Carrasco, N. Oligonerization ofthe Na+/I- symporter. In preparation.
24. Lin JD, Chan EC, Chao TC, et al. 2000 Expression of sodium iodide symporter in metastatic and follicular human thyroid tissues. Ann Oncol 11:625-9.
25. Ringel MD, Anderson J, Souza SL, et al. 2001 Expression of the sodium iodide symporter and thy-roglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 14:289-96.
26. Lin JD, Hsueh C, Chao TC, Weng HF 2001 Expression of sodium iodide symporter in benign and malignant human thyroid tissues. Endocr Pathol 12:15-21.
27. Arturi F, Russo D, Schlumberger M, et al. 1998 Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 83:2493-6.
28. Lazar V, Bidart JM, Caillou B, et al. 1999 Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84:3228-34.
29. Cazzola M, Skoda RC 2000 Translational pathophysiology: a novel molecular mechanism of human disease. Blood 95:3280-8.
30. Saito T, Endo T, Kawaguchi A, et al. 1998 Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 101:1296-300.
31. Wapnir IL, van de Rijn M, Nowels K, et al. 2003 Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 88:1880-8.
32. Russo D, Manole D, Arturi F, et al. 2001 Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas. Thyroid 11:37-9.
33. Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T 1997 Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 138:2227-32.
34. Ohno M, Zannini M, Levy O, Carrasco N, di Lauro R 1999 The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription. Mol Cell Biol 19:2051-60.
35. Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA 2002 A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3',5'-
response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol 16:2266-82.
36. Schmitt TL, Espinoza CR, Loos U 2002 Characterization of a thyroid-specific and cyclic adenosine monophosphate-responsive enhancer far upstream from the human sodium iodide symporter gene. Thyroid 12:273-9.
37. Kaminsky SM, Levy O, Salvador C, Dai G, Carrasco N 1994 Na(+)-I- symport activity is present in membrane vesicles from thyrotropin-deprived non-I(-)-transporting cultured thyroid cells. Proc Natl Acad Sci U S A 91:3789-93.
38. Glavy JS, Wu SM, Wang PJ, Orr GA, Wolkoff AW 2000 Down-regulation by extracellular ATP of rat hepatocyte organic anion transport is mediated by serine phosphorylation of oatp1. J Biol Chem 275:1479-84.
39. Krantz DE, Waites C, Oorschot V, et al. 2000 A phosphorylation site regulates sorting of the vesicular acetylcholine transporter to dense core vesicles. J Cell Biol 149:379-96.
40. Ramamoorthy S, Blakely RD 1999 Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285:763-6.
41. Plummer H, S. 1923 Results of administering iodine to patients having exophthalmic goiter. JAMA 80:1955.
42. Wolff J, Chaikoff, I.,L. 1948 Plasma inorganic iodide as a homeostatic regulator of thyroid function. Journal of Biological Chemistry 174:555-564.
43. Braverman LE, Ingbar, S.H. 1963 Changes in thyroidal function during adaptation to large doses of iodide. Journal of Clinical Investigations 42:1216-1231.
44. Panneels V, Van Sande J, Van den Bergen H, et al. 1994 Inhibition of human thyroid adenylyl cyclase by 2-iodoaldehydes. Mol Cell Endocrinol 106:41-50.
45. Grollman EF, Smolar A, Ommaya A, Tombaccini D, Santisteban P 1986 Iodine suppression of iodide uptake in FRTL-5 thyroid cells. Endocrinology 118:2477-82.
46. Uyttersprot N, Pelgrims N, Carrasco N, et al. 1997 Moderate doses of iodide in vivo inhibit cell proliferation and the expression of thyroperoxidase and Na+/I- symporter mRNAs in dog thyroid. Mol Cell Endocrinol 131:195-203.
47. Spitzweg C, Joba W, Morris JC, Heufelder AE 1999 Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 9:821-30.
48. Eng PH, Cardona GR, Previti MC, Chin WW, Braverman LE 2001 Regulation of the sodium iodide symporter by iodide in FRTL-5 cells. Eur J Endocrinol 144:139^44.
49. Eng PH, Cardona GR, Fang SL, et al. 1999 Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology 140:3404-10
50. Roger P, Taton M, Van Sande J, Dumont JE 1988 Mitogenic effects of thyrotropin and adenosine S'^'-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab 66:1158-65.
51. Takasu N, Ohno S, Komiya I, Yamada T 1992 Requirements of follicle structure for thyroid hormone synthesis; cytoskeletons and iodine metabolism in polarized monolayer cells on collagen gel and in double layered, follicle-forming cells. Endocrinology 131:1143-8.
52. Kogai T, Curcio F, Hyman S, Cornford EM, Brent GA, Hershman JM 2000 Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Endocrinol 167: 125-35.
53. Fitzgerald PJ, Foote, F.W. 1949 The function of of various types of thyroid carcinoma as revealed by the radioautographic demonstration of of radioactive iodine. J. Clin. Endocrinol. 9:11531170.
54. De Micco C, Kopp F, Vassko V, Grino M 2000 In situ hybridization and immunohistochemistry study of thyroid peroxidase expression in thyroid tumors. Thyroid 10:109-15.
55. Czarnocka B, Pastuszko D, Janota-Bzowski M, et al. 2001 Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer? Br J Cancer 85:875-80.
56. Christensen L, Blichert-Toft M, Brandt M, et al. 2000 Thyroperoxidase (TPO) immunostaining of the solitary cold thyroid nodule. Clin Endocrinol (Oxf) 53:161-9.
57. Smanik PA, Fithian LJ, Jhiang SM 1994 Thyroid peroxidase expression and DNA polymorphisms in thyroid cancer. Biochem Biophys Res Commun 198:948-54.
58. Valenta L 1966 Metastatic thyroid carcinoma in man concentrating iodine without organification. J Clin Endocrinol Metab 26:1317-24.
59. Cho JY 2002 A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy. Curr Gene Ther 2:393-402.
60. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC 2000 Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 60:6526-30.
61. Dingli D, Diaz RM, Bergert ER, O'Connor MK, Morris JC, Russell SJ 2003 Genetically targeted radiotherapy for multiple myeloma. Blood 102:489-96.
62. Spitzweg C, Dietz AB, O'Connor MK, et al. 2001 In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 8:1524-31.
63. Everett LA, Glaser B, Beck JC, et al. 1997 Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat Genet 17:411-22.
64. Mian C, Lacroix L, Alzieu L, et al. 2001 Sodium iodide symporter and pendrin expression in human thyroid tissues. Thyroid 11:825-30.
65. Scott DA, Wang R, Kreman TM, et al. 2000 Functional differences of the PDS gene product are associated with phenotypic variation in patients with Pendred syndrome and non-syndromic hearing loss (DFNB4). Hum Mol Genet 9:1709-15.
66. Everett LA, Belyantseva IA, Noben-Trauth K, et al. 2001 Targeted disruption of mouse Pds provides insight about the inner-ear defects encountered in Pendred syndrome. Hum Mol Genet 10:153-61.
67. Rodriguez AM, Perron B, Lacroix L, et al. 2002 Identification and characterization ofaputative human iodide transporter located at the apical membrane of thyrocytes. J Clin Endocrinol Metab 87:3500-3.
68. Li H, Myeroff L, Smiraglia D, et al. 2003 SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA 100:8412-7.
69. Rawson RW 1965 Physiological considerations in the management of thyroid cancer. Nucl Med (Stuttg):Suppl 2:319+.
70. Koch W, Knesewitsch P, Tatsch K, Hahn K 2003 [Stunning effects in radioiodine therapy of thyroid carcinoma: existence, clinical effects and ways out]. Nuklearmedizin 42:10-4.
71. Yeung HW, Humm JL, Larson SM 2000 Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J Nucl Med 41:1082-5.
72. Postgard P, Himmelman J, Lindencrona U, et al. 2002 Stunning of iodide transport by (131)I irradiation in cultured thyroid epithelial cells. J Nucl Med 43:828-34.
73. Robbins RJ, Tuttle RM, Sonenberg M, et al. 2001 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11:865-9.
74. Venkataraman GM, Yatin M, Marcinek R, Ain KB 1999 Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 84:2449-57.
75. Kitazono M, Robey R, Zhan Z, et al. 2001 Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86:3430-5.
76. Zarnegar R, Brunaud L, Kanauchi H, et al. 2002 Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132:984-90; discussion 990.
77. Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J 1997 Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 240:832-8.
78. Schmutzler C, Kohrle J 2000 Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10:393406.
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.